THE SPECIFIC FEATURES OF A RESPONSE TO A TYROSINE KINASE INHIBITOR AGAINST DIFFERENT HISTOLOGICAL TYPES OF KIDNEY CANCER (A REVIEW)

Cover Page

Cite item

Full Text

Abstract

The paper deals with the results of a clinical trial covering patients with disseminated renal cell carcinoma of different histological types, who had no benefits from previous systemic therapy. The response of different histological types of kidney cancer to therapy with tyrosine kinase inhibitors, to sorafenib in particular, was studied within the trial. The findings strongly suggest that mainly patients with clear-cell renal cell carcinoma could achieve complete or partial remission.

About the authors

A. D. Kaprin

People’s Friendship University of Russia, Moscow

Author for correspondence.
Email: andocrey@mail.ru
Department of Urology with a Course of Oncourology Russian Federation

A. A. Kostin

People’s Friendship University of Russia, Moscow

Email: andocrey@mail.ru
Department of Urology with a Course of Oncourology Russian Federation

V. V. Alekseev

People’s Friendship University of Russia, Moscow

Email: andocrey@mail.ru
Department of Urology with a Course of Oncourology Russian Federation

A. Yu. Varakina

People’s Friendship University of Russia, Moscow

Email: andocrey@mail.ru
Department of Urology with a Course of Oncourology Russian Federation

References

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c)



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36986 от  21.07.2009.